AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Original) A compound of the Formula (I):



(I)

or a salt, solvate, or physiologically functional derivative thereof wherein:

A is aryl, heteroaryl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, -CN, halo, -COOH, -C(O)NR^4R^5, –NRR', -N(R')$S(O)_2$R, -N(R')C(O)R, or –N(R')C(O)NR^4R^5;

R is –H, C_1-C_6 alkyl, aryl, or heteroaryl;

R' is –H or C_1-C_3 alkyl;

D is selected from the group consisting of:




, 
, 
, and 
;

R^2 is –H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, aryl, heteroaryl, -$S(O)_2NR^4R^5$, -COOH, -$C(O)OR^6$, -$C(O)NR^4R^5$, NRR', -N(H)C(O)NRR', -N(H)C(O)R, or –$N(H)S(O)_2R$;

q is 1, 2, 3, or 4;

R^3 is –H, C_1-C_3 alkyl, aryl, aralkyl, or heteroaryl;
R^4 is –H or C_1-C_3 alkyl;
R^5 is –H or C_1-C_3 alkyl; or
R^4 and R^5 together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen, $S(O)_m$, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C_1-C_3 alkyl group;
m is 0, 1, or 2; and
R^6 is C_1-C_6 alkyl.

2.(New) The compound of claim 1 wherein:

A is aryl optionally substituted with at least one R^1 group, heteroaryl optionally substituted with at least one R^1 group, C_1-C_6 alkenyl, C_1-C_6 alkynyl, -CN, halo, -COOH, -$C(O)NR^4R^5$, –NRR', -N(R')$S(O)_2$R, -N(R')C(O)R, or -N(R')$C(O)NR^4R^5$;

R is –H, C_1-C_6 alkyl, aryl, or heteroaryl;

R' is –H or C_1-C_3 alkyl;

R^1 is C_1-C_6 alkyl, aryl, C_1-C_6 alkoxy, aryloxy, halo, -COOH, -CN, -$S(O)_2NR^4R^5$, -$S(O)_2$R, -$C(O)NR^4R^5$, -NRR', -N(H)$C(O)NR^4R^5$, -$O(CH_2)_n$COOH, -$(CH_2)_n$COOH, -$C(O)O(CH_2)_n$R, -$(CH_2)_n$N(H)C(O)OR, or -N(R')$S(O)_2$R;

n is 1, 2, 3, or 4;

D is selected from the group consisting of:



;

R^2 is –H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, heteroaryl, $-S(O)_2NR^4R^5$, -COOH, $-C(O)OR^6$, or $-C(O)NR^4R^5$, NRR', -N(H)C(O)NRR', -N(H)C(O)R, or $-N(H)S(O)_2R$;

q is 1, 2, 3, or 4;

R^3 is –H, C_1-C_3 alkyl, aryl, aralkyl, or heteroaryl;

R^4 is –H or C_1-C_3 alkyl;

R^5 is –H or C_1-C_3 alkyl; or

R^4 and R^5 together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen, $S(O)_m$, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C_1-C_3 alkyl group;

m is 0, 1, or 2; and

R^6 is C_1-C_6 alkyl.

3. (New) The compound of claim 1 wherein:

A is aryl optionally substituted with at least one R^1 group or heteroaryl optionally substituted with at least one R^1 group;

R is –H, C_1-C_6 alkyl, aryl, or heteroaryl;

R' is –H or C_1-C_3 alkyl;

R^1 is C_1-C_6 alkyl, aryl, C_1-C_6 alkoxy, aryloxy, halo, -COOH, -CN, $-S(O)_2NR^4R^5$, $-S(O)_2R$, $-C(O)NR^4R^5$, -NRR', $-N(H)C(O)NR^4R^5$, $-O(CH_2)_nCOOH$, $-(CH_2)_nCOOH$, $-C(O)O(CH_2)_nR$, $-(CH_2)_nN(H)C(O)OR$, or $-N(R')S(O)_2R$;

D is selected from the group consisting of:


,

,

,

,

,

,

,

,

, and

;

R^2 is –H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, heteroaryl, $-S(O)_2NR^4R^5$, -COOH, $-C(O)OR^6$, or $-C(O)NR^4R^5$, NRR', $-N(H)C(O)NRR'$, $-N(H)C(O)R$, or $-N(H)S(O)_2R$;

q is 1, 2, 3, or 4;

R^3 is –H, C_1-C_3 alkyl, aryl, aralkyl, or heteroaryl;
R^4 is –H or C_1-C_3 alkyl;
R^5 is –H or C_1-C_3 alkyl; or
R^4 and R^5 together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen, $S(O)_m$, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C_1-C_3 alkyl group;
m is 0, 1, or 2; and
R^6 is C_1-C_6 alkyl.

4. (New) The compound of claim 1 wherein:
A is C_1-C_6 alkenyl or C_1-C_6 alkynyl;

R is –H, C_1-C_6 alkyl, aryl, or heteroaryl;

R' is –H or C_1-C_3 alkyl;

D is selected from the group consisting of:


,

,

,

,

,

,

,

,

, and

;

R^2 is –H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, heteroaryl, -$S(O)_2NR^4R^5$, -COOH, -$C(O)OR^6$, or -$C(O)NR^4R^5$, NRR', -N(H)C(O)NRR', -N(H)C(O)R, or -$N(H)S(O)_2R$;

q is 1, 2, 3, or 4;

R^3 is –H, C_1-C_3 alkyl, aryl, aralkyl, or heteroaryl;
R^4 is –H or C_1-C_3 alkyl;
R^5 is –H or C_1-C_3 alkyl; or
R^4 and R^5 together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen, $S(O)_m$, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C_1-C_3 alkyl group;
m is 0, 1, or 2; and
R^6 is C_1-C_6 alkyl.

5. (New) The compound of claim 1 wherein:

A is -CN, -COOH, or -$C(O)NR^4R^5$;

R is –H, C_1-C_6 alkyl, aryl, or heteroaryl;

R' is –H or C_1-C_3 alkyl;

D is selected from the group consisting of:




, 
, 
, and 
;

R^2 is –H, halo, C_1-C_6 alkyl, -COOH, C_1-C_6 alkoxy, heteroaryl, $-S(O)_2NR^4R^5$, $-C(O)OR^6$, or $-C(O)NR^4R^5$, NRR', -N(H)C(O)NRR', -N(H)C(O)R, or $-N(H)S(O)_2R$;

q is 1, 2, 3, or 4;

R^3 is –H, C_1-C_3 alkyl, aryl, aralkyl, or heteroaryl;
R^4 is –H or C_1-C_3 alkyl;
R^5 is –H or C_1-C_3 alkyl; or
R^4 and R^5 together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen, $S(O)_m$, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C_1-C_3 alkyl group;
m is 0, 1, or 2; and
R^6 is C_1-C_6 alkyl.

6. (New) The compound of claim 1 wherein:

A is –NRR', $-N(R')S(O)_2R$, -N(R')C(O)R, or $-N(R')C(O)NR^4R^5$;

R is –H, C_1-C_6 alkyl, aryl, or heteroaryl;

R' is –H or C_1-C_3 alkyl;

D is selected from the group consisting of:



R^2 is –H, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, heteroaryl, -$S(O)_2NR^4R^5$, -COOH, -$C(O)OR^6$, or -$C(O)NR^4R^5$, NRR', -N(H)C(O)NRR', -N(H)C(O)R, or -$N(H)S(O)_2R$;

q is 1, 2, 3, or 4;

R^3 is –H, C_1-C_3 alkyl, aryl, aralkyl, or heteroaryl;
R^4 is –H or C_1-C_3 alkyl;
R^5 is –H or C_1-C_3 alkyl; or
R^4 and R^5 together with the nitrogen to which they are attached form a heterocyclyl ring, said ring optionally containing 1 or 2 additional oxygen, $S(O)_m$, or nitrogen atoms; said nitrogen atoms being optionally substituted by a C_1-C_3 alkyl group;
m is 0, 1, or 2; and
R^6 is C_1-C_6 alkyl.

7. (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and one or more of pharmaceutically acceptable carriers, diluents and excipients.

8. (New) The compound of claim 1, wherein D is selected from the group consisting of:


and


9. (New) The compound of claim 8, wherein D is:



10. (New) The compound of claim 8, wherein D is:



11. (New) The compound of claim 1, wherein D is selected from the group consisting of:


and


12. (New) The compound of claim 11, wherein D is:



13. (New) The compound of claim 11, wherein D is:



14. (New) The compound of claim 1, wherein said compound is selected from the group consisting of:

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

5-bromo-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-phenylpyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(3,4,5-trimethoxyphenyl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-thien-2-ylpyrazin-2-amine;

5-(4-aminophenyl)-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-pyridin-3-ylpyrazin-2-amine;

3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-5-yl)pyrazin-2-amine;

3-[1-(2-methoxyethyl)-1H-benzimidazol-2-yl]-5-thien-2-ylpyrazin-2-amine;

3-(1H-benzimidazol-2-yl)-5-(3-fluorophenyl)pyrazin-2-amine;

3-(1H-benzimidazol-2-yl)-5-(4-fluorophenyl)pyrazin-2-amine;

4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]-N,N-dimethylbenzenesulfonamide;

3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)-5-[3-(methylsulfonyl)phenyl]pyrazin-2-amine;

3-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}propanoic acid;

{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

{3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenoxy}acetic acid;

N-{4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]phenyl}methanesulfonamide;

benzyl 4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzoate;

5-[4-(benzyloxy)phenyl]-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

5-[1,1'-biphenyl-3-yl)-3-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

4-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-ylbenzoic acid;
tert-butyl 3-[5-amino-6-(1-ethyl-1-H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-yl]benzylcabamate;

3 (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-pyrrol-2-yl)pyrazin-2-amine;

3 (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-5-(1H-indol-2-yl)pyrazin-2-amine; and

5-[(4-aminophenyl)ethynyl]-3-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)pyrazin-2-amine;

or a salt, solvate, or physiologically functional derivative thereof.

15. (New) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate ROCK-1 activity, comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.